

# LSP Life Sciences Fund

Monthly Report January 2019

**LSP**  
CONNECTING INVESTORS TO INVENTORS

NAV per Share € 231.98

## Performance

YTD	1 Month	3 Months	1 Year	2 Years	3 Years	5 Years
8.2%	8.2%	-2.6%	-10.5%	28.5%	34.0%	17.0%

## Top-5 performers

1. Aerie Pharmaceuticals	30.2%
2. Amarin Corp	28.6%
3. FibroGen	22.6%
4. Uniqure	18.8%
5. Evotec	17.8%

NAV of Fund	77,767,023
Number of Shares	335,221
Valuation Date	31/01/2019

Inception date:	27/04/2011
Currency:	Euro
Domicile:	The Netherlands
Legal Structure:	Dutch NV with variable capital
Listing:	Euronext Amsterdam
Euronext code:	LSP
ISIN Code:	NL0009756394
Bloomberg:	LSP NA


## Investment strategy

The Fund's primary investment objective is to achieve capital appreciation by investing in a diversified, yet concentrated portfolio of publicly listed life sciences companies (including biopharmaceutical-, specialist pharmaceutical-, medical device-, drug delivery-, vaccine- and diagnostic companies). The majority of the Fund's portfolio will consist of European companies listed on one of the (main) European stock exchanges, with a market capitalization of below € 2.5 billion at the time of investment.

## Manager's comments

The year kicked off as usual with the JP Morgan conference in San Francisco which brings together representatives from virtually every healthcare company for a hectic week of meetings and networking events. It also traditionally tests the temperature of the industry and sets the tone for the months ahead. The announcement of the \$74bn BMS, Celgene M&A deal certainly got people talking. This was quickly followed by the \$8bn acquisition of Loxo Oncology by Eli Lilly for its drug to treat rare forms of cancer. The LSP portfolio has a return of 8.2% for the month, which more than made up for the volatility at the end of 2018. The strongest performers for the month were Aerie, Amarin, Fibrogen and uniQure. Aerie launched its first product, a novel treatment for eye disease, glaucoma which has been tracking better than market expectations and the real world experience with the drug is proving to be excellent. Aerie is on track to have a second product approved by the FDA in March. Amarin shares jumped on the back on rumours of a Pfizer take over. Amarin has the data and the drug, Vascepa, is already on the market – the only question is how big that market will be and which company is best positioned to maximise the potential of the product. Fibrogen presented top line phase 3 data for its novel treatment for anemia – the shares are finally starting to reflect the strength of this data and recognize that Fibrogen is on track to file for approval later this year, once the full safety data analysis is available. In the closing days of 2019, uniQure presented very encouraging data for its exciting gene therapy for haemophilia B – as was the case for Fibrogen and indeed many other healthcare stocks – the good news was not reflected in the share price. We view the strong performance in the stock in January as a delayed response to the positive news flow. The global political landscape and market sentiment could potentially mean more volatility lies ahead. For the LSP fund we continue to seek out the companies and products which we believe have the potential to excel and add significant value to patients lives and to the shareholders who support them.

## Portfolio breakdown



# LSP Life Sciences Fund



## Portfolio breakdown

Company	Stage	Subsector	Marketcap	%
argenx	Late	Therapeutics	Mid	12.3%
Amarin Corp	Market	Therapeutics	Mid	8.1%
Galapagos	Late	Therapeutics	Mid	8.1%
Evotec	Early	Therapeutics	Mid	8.0%
Morphosys	Late	Therapeutics	Mid	6.7%
Uniqure	Late	Therapeutics	Small	6.1%
Aerie Pharmaceuticals	Market	Therapeutics	Mid	5.5%
ObsEva	Late	Therapeutics	Small	5.3%
Foamix Pharmaceuticals	Late	Therapeutics	Small	5.0%
Genmab	Market	Therapeutics	Mid	4.8%
Stemline Therapeutics	Late	Therapeutics	Small	4.7%
CytomX Therapeutics	Early	Therapeutics	Small	4.4%
Verastem	Late	Therapeutics	Small	3.8%
Cocrystal Pharma	Early	Therapeutics	Micro	3.4%
Merus	Early	Therapeutics	Small	3.4%
FibroGen	Late	Therapeutics	Mid	3.0%
Eloxx Pharmaceuticals	Early	Therapeutics	Small	1.8%
Viking Therapeutics	Early	Therapeutics	Mid	1.7%

### Important information

LSP Advisory B.V. (as Fund Manager) and the LSP Life Sciences Fund N.V. (the Fund) have a license and are registered pursuant to the Dutch Act on Financial Supervision and are supervised by the Stichting Autoriteit Financiële Markten (Dutch Authority for the Financial Markets) and De Nederlandsche Bank N.V. (the Dutch Central Bank). This presentation is solely for information purposes and is not intended as advice in any way. The Fund Manager and the Fund cannot be held liable or responsible for the content of this presentation. Potential investors are advised to contact their investment- and fiscal advisor prior to taking an investment decision. There are risks involved in the investment. The value of the investment can fluctuate. Results achieved in the past offer no guarantee for the future. A Key Investor Information Document is also available for this product with information about the product, the costs and the risks involved. Read it before you invest in the product. The prospectus and the Key Investor Information Document of the LSP Life Sciences Fund can be downloaded via [www.lspvc.com/funds/public.html](http://www.lspvc.com/funds/public.html)

In Switzerland, the Fund may only be offered or distributed to qualified investors. For this, the Fund has appointed as Swiss Representative Oligo Swiss Fund Services SA, Av. Villamont 17, 1005 Lausanne, Switzerland, Tel: +41 21 311 17 77, email: [info@oligofunds.ch](mailto:info@oligofunds.ch). The Fund's paying agent is Banque Cantonale de Genève. Any Fund Documentation may be obtained free of charge from the Swiss Representative in Lausanne.